Immune checkpoint therapy in liver cancer

Xu, Feng; Jin, Tianqiang; Zhu, Yuwen; Dai, Chaoliu

doi:10.1186/s13046-018-0777-4

Journal of Experimental & Clinical Cancer Research

Table 4 Ongoing clinical trials combining epigenetic drugs and immune checkpoint blockade therapy in cancers

From: Immune checkpoint therapy in liver cancer

Cancer type	Number	Immune checkpoint inhibitors	Epigenetic drugs	Stage	Status	Design	Trial NCT
HCC	90	Durvalumab	Guadecitabine	Phase 1	Recruiting	Single Group Assignment	NCT03257761
Unresectable NSCLC	41	Nivolumab and ipilimumab	ACY-241	Phase 1	Recruiting	Single Group Assignment	NCT02635061
Metastatic unresectable HER2-negative breast cancer	45	Pembrolizumab	Entinostat	Phase 1	Recruiting	Single Group Assignment	NCT02453620
Advanced solid tumors	30	Pembrolizumab	Entinostat	Phase 1	Recruiting	Randomized	NCT02909452
Unresectable stage III/IV melanoma	17	Ipilimumab	Panobinostat	Phase 1	Recruiting	Single Group Assignment	NCT02032810
Advanced CRC	30	Pembrolizumab	Romidepsin and/or 5-AZA	Phase 1	Recruiting	Randomized	NCT02512172
MSS advanced CRC	30	Pembrolizumab	Romidepsin and/or 5-AZA	Phase 1	Recruiting	Randomized	NCT02512172
MDS following DNMTi-failed therapy	27	Pembrolizumab	Entionstat	Phase 1	Recruiting	Single Group Assignment	NCT02936752
Advanced solid tumors or lymphomas	45	Nivolumab	RRx-001	Phase 1	Active, not recruiting	Single Group Assignment	NCT02518958
MM	19	Ipilimumab	SGI-110	Phase 1	Recruiting	Single Group Assignment	NCT02608437
MDS	73	Durvalumab with or without tremelimumab	Azacytidine	Phase 1	Recruiting	Non-Randomized	NCT02117219
Advanced cell carcinoma	62	Atezolizumab	Entinostat	Phase 1/2	Recruiting	Single Group Assignment	NCT03024437
Breast cancer	88	Atezolizumab	Entinostat	Phase 1/2	Recruiting	Randomized	NCT02708680
DLBCL	5	Rituximab	Belinostat	Phase 2	Active, not recruiting	Single Group Assignment	NCT01686165
Metastatic uveal melanoma	29	Pembrolizumab	Entinostat	Phase 2	Recruiting	Single Group Assignment	NCT02697630
DLBCL	42	Rituximab	Panobinostat	Phase 2	Active, not recruiting	Randomized	NCT01238692
Advanced solid tumors and NSCLC	119	Durvalumab	Mocetinostat	Phase 1/2	Recruiting	Single Group Assignment	NCT02805660
NSCLC and melanoma	202	Pembrolizumab	Entinostat	Phase 1/2	Recruiting	Non-Randomized	NCT02437136
HNSCC and SGC	49	Pembrolizumab	Vorinostat	Phase 1/2	Active, not recruiting	Single Group Assignment	NCT02538510
Stage IV NSCLC	100	Pembrolizumab	Vorinostat	Phase 1/2	Recruiting	Randomized	NCT02638090
DLBCL	83	Rituximab	Vorinostat	Phase 1/2	Active, not recruiting	Single Group Assignment	NCT00972478
Lymphoma/leukaemia	40	Rituximab	Vorinostat	Phase 1/2	Active, not recruiting	Single Group Assignment	NCT00918723
Advanced renal or urothelial cell carcinoma	42	Pembrolizumab	Vorinostat	Phase 2	Recruiting	Non-Randomized	NCT02619253
Hormone therapy-resistant breast cancer	87	Pembrolizumab	Vorinostat	Phase 2	Recruiting	Randomized	NCT02395627
AML	182	Nivolumab	5-AZA	Phase 2	Recruiting	Non-Randomized	NCT02397720
Metastatic CRC	31	Nivolumab	5-AZA	Phase 2	Active, not recruiting	Single Group Assignment	NCT02260440
Advanced/metastatic NSCLC	100	Nivolumab	5-AZA	Phase 2	Active, not recruiting	Randomized	NCT02546986
MDS	120	Nivolumab and/or ipilimumab	5-AZA	Phase 2	Recruiting	Non-Randomized	NCT02530463
Refractory/relapsed AML	37	Lirilumab	5-AZA	Phase 2	Active, not recruiting	Single Group Assignment	NCT02399917
MDS	12	Lirilumab and nivolumab	5-AZA	Phase 2	Active, not recruiting	Non-Randomized	NCT02599649
Metastatic melanoma	71	Pembrolizumab	5-AZA	Phase 2	Recruiting	Non-Randomized	NCT02816021
NSCLC	120	Nivolumab	5-AZA and/or entinostat	Phase 2	Recruiting	Randomized	NCT01928576
NSCLC	60	Nivolumab	5-AZA- CdR/tetrahydrouridine	Phase 2	Recruiting	Randomized	NCT02795923
Advanced solid tumors	60	Durvalumab	5-AZA	Phase 2	Recruiting	Single Group Assignment	NCT02811497
Advanced/metastatic NSCLC	100	Pembrolizumab	Oral azacytidine	Phase 2	Active, not recruiting	Randomized	NCT02546986
PR recurrent OC	38	Pembrolizumab	Guadecitabine	Phase 2	Recruiting	Single Group Assignment	NCT02901899
PR recurrent OC	20	Pembrolizumab	Oral azacytidine	Phase 2	Recruiting	Randomized	NCT02900560
MDS	120	Durvalumab	Oral azacytidine	Phase 2	Recruiting	Randomized	NCT02281084
MDS, AML	213	Durvalumab	Azacytidine	Phase 2	Active, not recruiting	Randomized	NCT02775903
Refractory/recurrent epithelial OC	138	Avelumab	Entinostat	Phase 2	Recruiting	Randomized	NCT02915523
DLBCL	304	Rituximab	5-AZA	Phase 3	Recruiting	Randomized	NCT02951156

HCC hepatocellular carcinoma, NSCLC Non-small cell lung cancer, HER2 human epidermal growth factor receptor 2, CRC colorectal cancer, 5-AZA Azacitydine, MSS Microsatellite stable, MDS Myelodysplastic syndromes, DNMTi DNA methyltransferase inhibitor, MM Multiple myeloma, DLBCL Diffuse large B cell lymphoma, HNSCC head and neck squamous cell carcinoma, SGC salivary gland cancer, AML Acute myeloid leukaemia, OC ovarian cancer

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com